Floatz logo

DACLIZUMAB

HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL)

monoclonal_antibodyPhase 4 / ApprovedDormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL) cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

DACLIZUMAB is also rated in:

relapsing-remitting multiple sclerosisDormant
BB
Indicative ·
68 / 100
View asset →
relapsing-remitting multiple sclerosisDormant
B
Indicative ·
62 / 100
View asset →
leukemiaDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →